Skip to main content

-

Technology Guidance - Drug

Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy Published on 2 September 2019


Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for treating children, aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who:
    • do not have significant joint contractures, i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle; and
    • are concurrently receiving ongoing supportive therapy, e.g. physiotherapy or occupational therapy.
Botulinum toxin type A must be administered by a physician specialising in paediatric neurological disorders or paediatric rehabilitation with experience in administering botulinum toxin type A.

Subsidy status

Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF does not apply to Botox 200 U injection vial, Dysport 300 U and 500 U injection vials, and Xeomin 50 U and 100 U injection vials.



Get Acrobat Readeropens in a new window
Back to Top